NCT03670888 is a Phase 1 clinical trial of JHL1101 in B Cell Lymphoma, sponsored by JHL Biotech, Inc..

Who is sponsoring NCT03670888?

NCT03670888 is sponsored by JHL Biotech, Inc..

What drugs are being tested in NCT03670888?

Interventions in NCT03670888: JHL1101, Rituximab.

What condition does NCT03670888 study?

NCT03670888 studies B Cell Lymphoma.

Is NCT03670888 still recruiting?

NCT03670888 is currently terminated. Last updated 9 January 2020.

Last reviewed 2020-01-09 · How we verify

NCT03670888

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study to Compare the Bioequivalence and Safety of JHL1101 and Rituximab in CD20 Positive B Cell Lymphoma Patients

Terminated Phase 1 Last updated 9 January 2020

What this trial tests

Phase 1 trial testing JHL1101 in B Cell Lymphoma in 1 participant. Terminated before completion.

Timeline

16 November 2018

Primary endpoint
19 March 2019

19 March 2019

Quick facts

Lead sponsor	JHL Biotech, Inc.
Phase	Phase 1
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	1
Start date	16 November 2018
Primary completion	19 March 2019
Estimated completion	19 March 2019
Sites	2 locations across China

Drugs / interventions tested

JHL1101 — full drug profile →
Rituximab — full drug profile →

Conditions studied

B Cell Lymphoma — all drugs for B Cell Lymphoma →

Sponsor

JHL Biotech, Inc. — full company profile →

Who can join

Adults 18 to 75, any sex, with B Cell Lymphoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a multicenter, randomized, double-blind, parallel group study to compare the PK, safety, tolerability, immunogenicity and PD of JHL1101 vs Rituxan in subjects with CD20-positive B cell lymphoma. The study duration is 13 weeks. Approximately 128 eligible subjects will be randomized in a 1:1 ratio to receive either JHL1101 (n=64) or Rituxan (n=64). Each subject will receive one intravenous (IV) infusions of the investigational product (IP) at the dose of 375mg/m2 on Day 1. Assessments of PK, safety, tolerability, immunogenicity, PD, and efficacy will be collected over the following 13-week period.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Biosimilar monoclonal antibodies for cancer treatment in adults.
Galvao TF, Livinalli A, Lopes LC, Zimmermann IR, et al · · 2024 · cited 2× · PMID 39607013 · DOI 10.1002/14651858.cd013539.pub2

Verify or expand the search:

Other trials of JHL1101

Trials testing the same drug.

NCT03670901 — A Study to Compare the Efficacy and Safety of JHL1101 Versus Rituximab in Patients With Previously Untreated Diffuse Lar · Phase 3 · terminated
NCT03161457 — A Study of JHL1101 Versus MabThera® in Subjects With Severe Rheumatoid Arthritis · Phase 1 · terminated

Other recruiting trials for B Cell Lymphoma

Currently open trials in the same condition.

NCT07009002 — BCOR and ZC3H12 Genes Knock-out CD19-targeting CAR-T Cell Therapy in r/r B Cell Lymphoma · Phase 1, PHASE2 · recruiting
NCT06976437 — A Clinical Study of Allogeneic CD19/BCMA CAR-T Cells for the Treatment of R/R B-cell Malignant Tumors · EARLY_PHASE1 · recruiting
NCT06987916 — Efficacy and Safety Evaluation of U01(ssCART-19) in B-Cell Lymphoma · Phase 1, PHASE2 · recruiting
NCT07101913 — Occurrence of Acute Kidney Injury After CAR-T Cells Treatments in B-cell Lymphoma. · active not recruiting
NCT06742996 — A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib · Phase 3 · recruiting

Other JHL Biotech, Inc. trials

Trials by the same sponsor.

NCT03670901 — A Study to Compare the Efficacy and Safety of JHL1101 Versus Rituximab in Patients With Previously Untreated Diffuse Lar · Phase 3 · terminated
NCT03576651 — A Study to Compare the Pharmacokinetics of JHL1149 and Bevacizumab (Avastin) in Healthy Male Volunteers · Phase 1 · completed
NCT03586076 — A Comparative Safety and Pharmacokinetic Study of JHL1922 and Pulmozyme® in Healthy Subjects · Phase 1 · completed
NCT03161457 — A Study of JHL1101 Versus MabThera® in Subjects With Severe Rheumatoid Arthritis · Phase 1 · terminated

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03670888 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by JHL Biotech, Inc.
Last refreshed: 9 January 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03670888.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing